WO2011106986A1 - Inhibiteurs de polymérase du virus de l'hépatite c ns5b - Google Patents

Inhibiteurs de polymérase du virus de l'hépatite c ns5b Download PDF

Info

Publication number
WO2011106986A1
WO2011106986A1 PCT/CN2010/080332 CN2010080332W WO2011106986A1 WO 2011106986 A1 WO2011106986 A1 WO 2011106986A1 CN 2010080332 W CN2010080332 W CN 2010080332W WO 2011106986 A1 WO2011106986 A1 WO 2011106986A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
mhz
nmr
hcv
Prior art date
Application number
PCT/CN2010/080332
Other languages
English (en)
Inventor
Casey Cameron Mccomas
Nigel J. Liverton
Richard Soll
Peng Li
Xuanjia Peng
Hao Wu
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2010/070831 external-priority patent/WO2011106929A1/fr
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Priority to PCT/CN2010/080332 priority Critical patent/WO2011106986A1/fr
Priority to ARP110100621A priority patent/AR080433A1/es
Priority to TW100106743A priority patent/TW201136919A/zh
Priority to CA2791426A priority patent/CA2791426A1/fr
Priority to EP11750145.2A priority patent/EP2542545A4/fr
Priority to PCT/CN2011/000332 priority patent/WO2011106992A1/fr
Priority to AU2011223394A priority patent/AU2011223394A1/en
Priority to US13/582,240 priority patent/US20120328569A1/en
Priority to JP2012555284A priority patent/JP2013521237A/ja
Publication of WO2011106986A1 publication Critical patent/WO2011106986A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present disclosure relates to antiviral compounds that are useful as inhibitors of the hepatitis C virus (HCV) NS5B (non- structural protein 5B) polymerase, compositions comprising such compounds, the use of such compounds for treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection, methods for inhibiting the function of the NS5B polymerase, and methods for inhibiting HCV viral replication and/or viral production.
  • HCV hepatitis C virus
  • HCV infection is a major health problem that leads to chronic liver disease, such as cirrhosis and hepatocellular carcinoma, in a substantial number of infected individuals.
  • Current treatments for HCV infection include immunotherapy with recombinant interferon-a alone or in combination with the nucleoside analog ribavirin.
  • RNA-dependent RNA polymerase RNA-dependent RNA polymerase
  • HCV NS5B polymerase Sven-Erik Behrens et al, Identification and properties of the RNA-dependent RNA polymerase of heptatitis C virus, 15(1) EMBO J. 12-22 (1996). Antagonists of NS5B activity are inhibitors of HCV replication. Steven S . Carroll et al, Inhibition of Hepatitis C Virus RNA Replication by 2 '- Modified Nucleoside Analogs, 278(14) J. BlOL. CHEM. 11979-84 (2003).
  • novel Compounds of Formula (I) and/or pharmaceutically acceptable salts thereof are useful, either as compounds or their pharmaceutically acceptable salts (when appropriate), in the inhibition of HCV (hepatitis C virus) NS5B (non- structural 5B) polymerase, the prevention or treatment of one or more of the symptoms of HCV infection, the inhibition of HCV viral replication and/or HCV viral production, and/or as pharmaceutical composition ingredients.
  • these compounds and their salts may be the primary active therapeutic agent, and, when appropriate, may be combined with other therapeutic agents including but not limited to other HCV antivirals, anti-infectives, immunomodulators, antibiotics or vaccines, as well as the present standard of care treatment options for HCV
  • Z is a phenyl group which is substituted with one R 10 group and optionally further substituted with up to four R 20 groups;
  • R 10 is an 8- to 10-membered bicyclic heteroaryl group, wherein said 8- to 10- membered bicyclic heteroaryl group is optionally substituted with up to 4 groups, which can be the same or different, and are selected from halo, Ci-C 6 alkyl, -C(0)H, -(CH 2 ) r N(R 70 ) 2 , -(CH 2 ) r OH, -(CH 2 ) r O-(Ci-C 6 alkyl), -CF 3 , - HC(0)-heterocyclyl, - HC(0)-(Ci-C 6 alkyl), -C(0)NH- (Ci-C 6 alkyl), -C(0)OH, -C(0)0-(Ci-C 6 alkyl), -NHC(0)-aryl, - HS0 2 -aryl, - HS0 2 -alkyl, -O- S0 2 -alkyl, -0-(Ci-C 6
  • R 20 represents up to 4 optional substituents, which can be the same or different, and are selected from halo, 8- to 10-membered heteroaryl, C1-C5 alkyl, -0-(Ci-C6 alkyl), -O- (CH 2 )t-OH, -0-(CH 2 )t-heterocyclyl, -0-(Ci-C 6 haloalkyl), -0-S0 2 -(Ci-C 6 alkyl) and -CN;
  • R 30 is H or Ci-C 6 alkyl
  • R 4U is selected from Ci-C 6 alkyl, Ci-C 6 haloalkyl, -(CH 2 ) r OH, -(CH 2 ) r heterocyclyl,-(CH 2 ) t -N(R 70 ) 2 , -(CH 2 ) r CN, -(CH 2 ) r HC(0)OR 30 and -(CH 2 ) r HC(0)R 30 ;
  • R 50 is Ci-C 6 alkyl, C 6 -Cio aryl or C3-C7 cycloalkyl;
  • R 60 represents up to 4 optional ring substituents, which can be the same or different, and are selected from halo, C 1 -C5 alkyl, -0-(Ci-C 6 alkyl), -0-(Ci-C 6 haloalkyl) and - CN;
  • each occurrence of R 70 is independently H or C 1 -C5 alkyl
  • each occurrence of t is independently an integer ranging from 0 to 6.
  • the present invention also includes pharmaceutical compositions containing a compound of the present invention and methods of preparing such pharmaceutical compositions.
  • the present invention further includes methods of treating or reducing the likelihood or severity of HCV infection, methods for inhibiting the activity of the NS5B polymerase, and methods for inhibiting HCV viral replication and/or viral production.
  • the present invention includes Compounds of Formula (I) above, and pharmaceutically acceptable salts thereof.
  • the Compounds of Formula (I) are HCV NS5B polymerase inhibitors.
  • Z is:
  • Z is selected from:
  • each occurrence of R is independently CI, F, CN, -OCF 3 or -OCH 3 .
  • Z is selected from:
  • R is:
  • Z is selected from:
  • R is independently CI, F, CN, -OCF 3 or -OCH 3 ; and R 10 is selected from:
  • Z is selected from:
  • R is independently CI, F, CN, -OCF3 or -OCH 3 ; and R is selected from:
  • Z is selected from:
  • R is -CH 3 .
  • R 40 is Ci-C 6 alkyl, Ci-C 6 haloalkyl, -(CH 2 ) t -OH or -(CH 2 ) r CN, wherein t is an integer ranging from 0 to 6.
  • R 40 is Ci-C 6 alkyl.
  • R 40 is -CH 3 , - (CH 2 ) 3 -CN, -CH 2 CH 2 F, or -CH 2 CH 2 C(CH 3 ) 2 -OH.
  • R 40 is -CH 3 .
  • R is Ci-C 6 alkyl.
  • R is C 6 -Cio aryl.
  • R 50 is C3-C7 cycloalkyl.
  • R 50 is -CH 3 , phenyl or cyclopropyl.
  • R 50 is -CH 3 .
  • R represents a single halo group.
  • R 60 represents a single F group.
  • R 60 represents a single F group at the para position of the phenyl ring to which it is attached.
  • R is -CH 3 , -(CH 2 ) 3 -CN, -
  • R 40 and R 50 are each -CH 3 .
  • R 30 , R 40 and R 50 are each -CH 3 .
  • R 40 is -CH 3 , -(CH 2 ) 3 -CN, -CH 2 CH 2 F or -CH 2 CH 2 C(CH 3 ) 2 -OH;
  • R 50 is -CH 3 ; and
  • R 60 represents a single F group at the para position of the phenyl ring to which it is attached.
  • R 30 is -CH 3 ;
  • R 40 is -CH 3 , - (CH 2 ) 3 -CN, -CH 2 CH 2 F or -CH 2 CH 2 C(CH 3 ) 2 -OH;
  • R 50 is -CH 3 ;
  • R 60 represents a single F group at the para position of the phenyl ring to which it is attached.
  • R 30 , R 40 and R 50 are each -CH 3 and R 60 represents a single F group at the para position of the phenyl ring to which it is attached.
  • R is a 9-membered bicyclic heteroaryl group, wherein said 9-membered bicyclic heteroaryl group is optionally substituted with up to 2 groups, which can be the same or different, and are selected from halo, Ci-C 6 alkyl, -(CH 2 )t-N(R 70 ) 2 , -(CH 2 ) r OH, -(CH 2 ) r O-(Ci-C 6 alkyl), - CF 3 , - HC(0)-heterocyclyl, - HC(0)-(Ci-C 6 alkyl), -C(0) H-(d-C 6 alkyl), -C(0)OH, - C(0)0-(Ci-C 6 alkyl), - HC(0)-aryl, - HS0 2 -aryl, - HS0 2 -alkyl, -0-S0 2 -alkyl,-0-(Ci-C 6 alkyl) and -CN, wherein the
  • R 20 represents up to 2 optional substituents, which can be the same or different, and are selected from halo, Ci-C 6 alkyl, -0-(Ci-C 6 alkyl), -0-(CH 2 ) r OH, -0-(CH 2 ) r heterocyclyl, -0-(Ci-C 6 haloalkyl), -0-S0 2 -(Ci-C 6 alkyl) and -CN;
  • R 40 is Ci-C 6 alkyl, Ci-C 6 haloalkyl, -(CH 2 ) r OH or -(CH 2 ) r CN; and each occurrence of t is independently an integer ranging from 0 to 6.
  • R is selected from:
  • Z is selected from:
  • Z is:
  • Z is:
  • Z is:
  • Z is:
  • Z is:
  • Z is:
  • Z is:
  • R is Ci-C 6 alkyl.
  • R 40 is -CH 3 , -(CH 2 ) 3 -CN, - CH 2 CH 2 F, or -CH 2 CH 2 C(CH 3 ) 2 -OH. In a fifth aspect of this twelfth embodiment, R 40 is -CH 3 .
  • Z is selected from:
  • R 4U is -CH 3 , -(CH 2 ) 3 -CN, -CH 2 CH 2 F, or -CH 2 CH 2 C(CH 3 ) 2 -OH.
  • Z is selected from:
  • R 4U is -CH 3 .
  • Z is:
  • the compound of the invention is selected from Compounds 1-256 shown in the Examples below, and
  • compositions comprising an effective amount of a Compound of Formula (I) and a pharmaceutically acceptable carrier.
  • HCV antiviral agent is an antiviral selected from the group consisting of direct inhibitors of HCV, including but not limited to NS3 and NS3/4A protease inhibitors, NS5 A inhibitors and HCV NS5B polymerase inhibitors.
  • a pharmaceutical combination that is (i) a Compound of Formula (I) and (ii) a second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents; wherein the Compound of Formula (I) and the second therapeutic agent are each employed in an amount that renders the combination effective for inhibiting HCV NS5B activity, or for inhibiting HCV viral replication, or for treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection.
  • HCV antiviral agents are one or more antiviral agents selected from the group consisting of direct inhibitors of HCV, including but not limited to NS3 and NS3/4A protease inhibitors, NS5A inhibitors and HCV NS5B polymerase inhibitors.
  • HCV antiviral agent is an antiviral selected from the group consisting of direct inhibitors of HCV, including but not limited to NS3 and NS3/4A protease inhibitors, NS5A inhibitors and HCV NS5B polymerase inhibitors.
  • (k) A method of inhibiting HCV viral replication and/or HCV viral production in a cell-based system, which comprises administering to the subject an effective amount of a Compound of Formula (I) in combination with an effective amount of at least one second therapeutic agent selected from the group consisting of HCV antiviral agents,
  • HCV antiviral agent is an antiviral selected from the group consisting of direct inhibitors of HCV, including but not limited to NS3 and NS3/4A protease inhibitors, NS5A inhibitors and HCV NS5B polymerase inhibitors.
  • a method of inhibiting HCV NS5B activity in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), or (c) or the combination of (d) or (e).
  • each embodiment may be combined with one or more other embodiments, to the extent that such a combination provides a stable compound or salt and is consistent with the description of the embodiments. It is further to be understood that the embodiments of compositions and methods provided as (a) through (n) above are understood to include all embodiments of the compounds and/or salts, including such embodiments as result from combinations of embodiments.
  • Additional embodiments of the invention include the pharmaceutical compositions, combinations, uses and methods set forth in (a) through (n) above, wherein the compound of the present invention employed therein is a compound of one of the embodiments, aspects, classes, sub-classes, or features of the compounds described above.
  • the compound may optionally be used in the form of a pharmaceutically acceptable salt or hydrate as appropriate.
  • the present invention also includes a compound of the present invention for use
  • the compounds of the present invention can optionally be employed in combination with one or more second therapeutic agents selected from HCV antiviral agents, anti-infective agents, and immunomodulators.
  • alkyl refers to any linear or branched chain alkyl group having a number of carbon atoms in the specified range.
  • “Ci_6 alkyl” refers to all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
  • “Ci- 4 alkyl” refers to n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. Alkyl groups may be substituted as indicated.
  • halogenated refers to a group or molecule in which a hydrogen atom has been replaced by a halogen.
  • haloalkyl refers to a halogenated alkyl group.
  • halogen refers to atoms of fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo).
  • alkoxy refers to an "alkyl-O-" group. Alkoxy groups may be substituted as indicated.
  • cycloalkyl refers to any cyclic ring of an alkane or alkene having a number of carbon atoms in the specified range.
  • C3-8 cycloalkyl (or “C3-C8 cycloalkyl”) refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, and cyclooctenyl.
  • cycloalkoxy refers to a "cycloalkyl-O-" group.
  • Cycloalkyl groups may be substituted as indicated.
  • aryl refers to aromatic mono- and poly- carbocyclic ring systems wherein the individual carbocyclic rings in the polyring systems are fused or attached to each other via a single bond.
  • aryl includes aromatic mono- and poly-carbocyclic ring systems that include from 0 to 4 heteroatoms (non-carbon atoms) that are independently chosen from N, O and S.
  • Suitable aryl groups include phenyl, naphthyl, biphenylenyl, pyridinyl, pyrimidinyl and pyrrolyl, as well as those discussed below.
  • Aryl groups may be substituted as indicated.
  • Aryl ring systems may include, where appropriate, an indication of the variable to which a particular ring atom is attached.
  • Illustrative examples of aryl groups include phenyl, naphthyl and anthracenyl.
  • an aryl group is phenyl.
  • substituents to the aryl ring systems can be attached to any ring atom, provided that such attachment results in formation of a stable ring system.
  • carbocycle (and variations thereof such as “carbocyclic”) as used herein, unless otherwise indicated, refers to (i) a C5 to C 7 monocyclic, saturated or unsaturated ring, or (ii) a C 8 to C 10 bicyclic saturated or unsaturated ring system. Each ring in (ii) is either independent of, or fused to, the other ring, and each ring is saturated or unsaturated. Carbocycle groups may be substituted as indicated. When the carbocycles contain one or more heteroatoms independently chosen from N, O and S, the carbocycles may also be referred to as
  • heterocycles as defined below.
  • the carbocycle may be attached to the rest of the molecule at any carbon or nitrogen atom that results in a stable compound.
  • the fused bicyclic carbocycles are a subset of the carbocycles; i.e. , the term "fused bicyclic carbocycle” generally refers to a C 8 to Cio bicyclic ring system in which each ring is saturated or unsaturated and two adjacent carbon atoms are shared by each of the rings in the ring system.
  • a fused bicyclic carbocycle in which both rings are saturated is a saturated bicyclic ring system.
  • Saturated carbocyclic rings are also referred to as cycloalkyl rings, e.g. , cyclopropyl, cyclobutyl, etc.
  • a fused bicyclic carbocycle in which one or both rings are unsaturated is an unsaturated bicyclic ring system.
  • Carbocycle ring systems may include, where appropriate, an indication of the variable to which a particular ring atom is attached. Unless otherwise indicated, substituents to the ring systems can be attached to any ring atom, provided that such attachment results in formation of a stable ring system.
  • heterocyclic or “heterocyclyl” broadly refers to (i) a stable 5- to 7-membered, saturated or unsaturated monocyclic ring, or (ii) a stable 8- to 10-membered bicyclic ring system, wherein each ring in (ii) is independent of, or fused to, the other ring or rings and each ring is saturated or unsaturated, and the monocyclic ring or bicyclic ring system contains one or more heteroatoms (e.g., from 1 to 6 heteroatoms, or from 1 to 4 heteroatoms) independently selected from N, O and S and a balance of carbon atoms (the monocyclic ring typically contains at least one carbon atom and the bicyclic ring systems typically contain at least two carbon atoms); and wherein any one or more of the ring nitrogen and ring sulfur heteroatoms is optionally oxidized, for example to provide a ring N-oxide group or a ring -S(0) 2 - group, and any one or more
  • heterocyclic ring may be attached at any heteroatom or carbon atom, provided that attachment results in the creation of a stable structure.
  • Heterocycle groups may be substituted as indicated, and unless otherwise specified, the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results.
  • Representative examples include piperidinyl, piperazinyl, azepanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl (or tetrahydrofuranyl).
  • heteroaryl ring system refers to aryl ring systems, as defined above, that include from 1 to 4 heteroatoms (non-carbon atoms) that are independently chosen from N, O and S.
  • heteroatoms non-carbon atoms
  • substituted heteraromatic rings containing at least one nitrogen atom e.g., pyridine
  • such substitutions can be those resulting in N-oxide formation.
  • heteroaromatic rings include pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl (or thiophenyl), thiazolyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, and thiadiazolyl.
  • bicyclic heterocycles include benzotriazolyl, indolyl, isoindolyl, indazolyl, indolinyl, isoindolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, chromanyl, isochromanyl, tetrahydroquinolinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl,
  • alkyl, cycloalkyl, and aryl groups are not substituted.
  • the substituents are selected from the group which includes, but is not limited to, halo, Ci-C 2 o alkyl, -CF 3 , -NH 2 , -N(Ci-C 6 alkyl) 2 , -N0 2 , oxo, - CN, -N 3 , -OH, -0(Ci-C 6 alkyl), C 3 -Ci 0 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, (C 0 -C 6 alkyl) S(0)o-2-, aryl-S(O) 0.2 -, (C 0 -C 6 alkyl)S(0) 0 - 2 (Co-C 6 alkyl)-, (C 0 -C 6 alkyl)C(0)NH-,
  • the term “compound” is intended to encompass chemical agents described by generic Formula (I) in all forms, including hydrates and solvates of such chemical agents.
  • the term “compound” is intended to encompass prodrugs of the chemical agents described by generic Formula (I).
  • the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature.
  • the present invention is meant to include all suitable isotopic variations of the Compounds of Formula (I).
  • different isotopic forms of hydrogen (H) include protium (1H) and deuterium ( 2 H or D).
  • Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
  • Isotopically-enriched compounds within Formula (I) can be prepared without undue
  • heteroaryl ring described as containing from “ 1 to 3 heteroatoms” means the ring can contain 1, 2, or 3 heteroatoms. It is also to be understood that any range cited herein includes within its scope all of the sub-ranges within that range. The oxidized forms of the heteroatoms N and S are also included within the scope of the present invention.
  • any variable for example, R 20 or R 60
  • its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • a “stable” compound is a compound that can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein ⁇ e.g., therapeutic or prophylactic administration to a subject).
  • substituents and substituent patterns certain of the compounds of the present invention can have asymmetric centers and can occur as mixtures of stereoisomers, or as individual diastereomers, or enantiomers. All isomeric forms of these compounds, whether isolated or in mixtures, are within the scope of the present invention.
  • a reference to a Compound of Formula (I) is a reference to the compound per se, or to any one of its tautomers per se, or to mixtures of two or more tautomers.
  • the compounds of the present inventions are useful in the inhibition of HCV replication (e.g., HCV NS5B activity), the treatment of HCV infection and/or reduction of the likelihood or severity of symptoms of HCV infection.
  • HCV replication e.g., HCV NS5B activity
  • the compounds of this invention are useful in treating infection by HCV after suspected past exposure to HCV by such means as blood transfusion, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.
  • the compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds.
  • the compounds of this invention are useful for identifying resistant HCV replicon cell lines harboring mutations within NS5B, which are excellent screening tools for more powerful antiviral compounds.
  • the compounds of this invention are useful in establishing or determining the binding site of other antivirals to the HCV replicase.
  • the compounds of the present invention may be administered in the form of pharmaceutically acceptable salts.
  • pharmaceutically acceptable salt refers to a salt that possesses the effectiveness of the parent compound and that is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof).
  • Suitable salts include acid addition salts that may, for example, be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid.
  • suitable pharmaceutically acceptable salts thereof can include alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts.
  • pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
  • administration and variants thereof (e.g., “administering" a compound) in reference to a compound of the invention mean providing the compound or a prodrug of the compound to the individual in need of treatment.
  • active agents e.g., antiviral agents useful for treating HCV infection
  • “administration” and its variants are each understood to include concurrent and sequential provision of the compound or salt and other agents.
  • composition is intended to encompass a product comprising the specified ingredients, as well as any product which results, directly or indirectly, from combining the specified ingredients.
  • pharmaceutically acceptable is meant that the ingredients of the pharmaceutical composition must be compatible with each other and not deleterious to the recipient thereof.
  • subject refers to human or a chimpanzee. In one embodiment, the subject is a human.
  • the term "effective amount” as used herein means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
  • the effective amount is a "therapeutically effective amount” for the alleviation of one or more symptoms of the disease or condition being treated.
  • the effective amount is a "prophylactically effective amount” for reduction of the severity or likelihood of one or more symptoms of the disease or condition.
  • the effective amount is a "therapeutically effective amount” for inhibition of HCV viral replication and/or HCV viral production.
  • the term also includes herein the amount of active compound sufficient to inhibit HCV NS5B activity and thereby elicit the response being sought (i.e., an "inhibition effective amount").
  • an “inhibition effective amount” When the active compound (i.e., active ingredient) is administered as the salt, references to the amount of active ingredient are to the free acid or free base form of the compound.
  • the compounds of the present invention can be administered by any means that produces contact of the active agent with the agent's site of action. They can be administered by one or more
  • Liquid preparations suitable for oral administration can be prepared according to techniques known in the art and can employ any of the usual media such as water, glycols, oils, alcohols and the like.
  • Solid preparations suitable for oral administration e.g., powders, pills, capsules and tablets
  • solid excipients as starches, sugars, kaolin, lubricants, binders,
  • Parenteral compositions can be prepared according to techniques known in the art and typically employ sterile water as a carrier and optionally other ingredients, such as solubility aids.
  • injectable solutions can be prepared according to methods known in the art wherein the carrier comprises a saline solution, a glucose solution or a solution containing a mixture of saline and glucose. Further description of methods suitable for use in preparing pharmaceutical compositions of the present invention and of ingredients suitable for use in said compositions is provided in Remington: The Science and Practice of Pharmacy. 21 st edition (ed. University of the Sciences in Philadelphia; Lippincott, Williams & Wilkins, 2005).
  • the compounds of this invention can be administered orally in a dosage range of 0.001 to 1000 mg/kg of mammal (e.g., human) body weight per day in a single dose or in divided doses.
  • mammal e.g., human
  • One dosage range is 0.01 to 500 mg/kg body weight per day orally in a single dose or in divided doses.
  • Another dosage range is 0.1 to 100 mg/kg body weight per day orally in single or divided doses.
  • the compositions can be provided in the form of tablets or capsules containing 1.0 to 500 mg of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, HCV viral genotype, viral resistance, and the host undergoing therapy.
  • the present invention also relates to a method of inhibiting HCV NS5B activity, inhibiting HCV viral replication and/or HCV viral production, treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection with a compound of the present invention in combination with one or more therapeutic agents and a pharmaceutical composition comprising a compound of the present invention and one or more therapeutic agents selected from the group consisting of a HCV antiviral agent, an
  • Such therapeutic agents active against HCV include, but are not limited to, ribavirin, levovirin, viramidine, thymosin alpha- 1, R7025 (an enhanced interferon (Roche)), interferon- ⁇ , interferon- ⁇ , pegylated interferon- ⁇ (peginterferon-a), a combination of interferon- ⁇ and ribavirin, a combination of peginterferon- ⁇ and ribavirin, a combination of interferon- ⁇ and levovirin, and a combination of peginterferon- ⁇ and levovirin.
  • Interferon- ⁇ includes, but is not limited to, recombinant interferon-a2a (such as ROFERON interferon available from Hoffmann- LaRoche, Nutley, NJ), pegylated interferon-a2a (PEGASYS), interferon-a2b (such as INTRON-A interferon available from Schering Corp., Kenilworth, NJ), pegylated interferon-a2b
  • interferon-a2a such as ROFERON interferon available from Hoffmann- LaRoche, Nutley, NJ
  • PEGASYS pegylated interferon-a2a
  • interferon-a2b such as INTRON-A interferon available from Schering Corp., Kenilworth, NJ
  • the compounds of the invention may also be administered in combination with an antiviral agent NS5B polymerase inhibitor, e.g., R7128 (Roche), valopicitabine (NM-283; Idenix) and 2'-F-2'-beta-methylcytidine (see also WO
  • the compounds of the present invention also may be combined for the treatment of HCV infection with antiviral 2'-C-branched ribonucleosides disclosed in Rogers E. Harry-O'Kuru et al. , A Short, Flexible Route toward 2 '-C-Branched Ribonucleosides, 62 J. ORG. CHEM. 1754-59 (1997); Michael S. Wolfe & Rogers E. Harry-O'Kuru, A Concise Synthesis o/2'-C- Methylribonucleosides, 36(42) TETRAHEDRON LETTERS 761 1 - 14 ( 1995); U. S . Patent
  • Such 2'-C-branched ribonucleosides include, but are not limited to, 2'-C-methyl-cytidine, 2'-C-methyl-uridine, 2'-C-methyl-adenosine, 2'-C-methyl- guanosine, and 9-(2-C-methyl-P-D-ribofuranosyl)-2,6-diaminopurine, and the corresponding amino acid ester of the ribose C-2', C-3 ', and C-5' hydroxyls and the corresponding optionally substituted cyclic 1,3 -propanediol esters of the 5'-phosphate derivatives.
  • the compounds of the present invention may also be administered in combination with an agent that is an inhibitor of HCV NS3 serine protease.
  • HCV NS3 serine protease is an essential viral enzyme and has been described to be an excellent target for inhibition of HCV replication.
  • Exemplary substrate and non-substrate based inhibitors of HCV NS3 protease inhibitors are disclosed in International Patent Application Publications WO 98/22496, WO 98/46630, WO 99/07733, WO 99/07734, WO 99/38888, WO 99/50230, WO 99/64442, WO 00/09543, WO 00/59929, WO 02/481 16, WO 02/48172, WO 2008/057208 and WO 2008/057209, in British Patent No. GB 2 337 262, and in U. S. Patent Nos. 6,323, 180 and 7,470,664.
  • HCV protease inhibitors useful in the present compositions and methods include, but are not limited to, the following compounds:
  • the compounds of the present invention may also be combined for the treatment of HCV infection with nucleosides having anti-HCV properties, such as those disclosed in International Patent Application Publications WO 02/51425, WO 01/79246, WO 02/32920, WO 02/48165 and WO 2005/003147 (including R1656, (2'R)-2'-deoxy-2'-fluoro-2'-C- methylcytidine, shown as compounds 3 ⁇ 6 on page 77); WO 01/68663; WO 99/43691 ;
  • the compounds of the present invention may also be administered in combination with an agent that is an inhibitor of HCV NS5B polymerase.
  • HCV NS5B polymerase inhibitors that may be used as combination therapy include, but are not limited to, those disclosed in International Patent Application Publications
  • additional nucleoside HCV NS5B polymerase inhibitors that are used in combination with the present HCV NS5B inhibitors are selected from the following compounds: 4-amino-7-(2-C-methyl-P-D-arabinofuranosyl)-7H-pyrrolo[2,3- ⁇ JJpyrimidine; 4- amino-7-(2-C-methyl-P-D-ribofuranosyl)-7H-pyrrolo[2,3-ii ]pyrimidine; 4-methylamino-7-(2-C- methyl-P-D-ribofuranosyl)-7H-pyrrolo[2,3-ii ]pyrimidine; 4-dimethylamino-7-(2-C-methyl-P-D- ribofuranosyl)-7H-pyrrolo[2,3-ii?]pyrimidine; 4-cyclopropylamino-7-(2-C-methyl-P-D- ribofuranosyl)-7H-pyrrolo[2,3-ii?]pyrimidine; 4-
  • the compounds of the present invention may also be combined for the treatment of HCV infection with non-nucleoside inhibitors of HCV polymerase such as those disclosed in U.S. Patent Applciation Publications US 2006/0100262 and US 2009/0048239; International Patent Application Publications WO 01/77091, WO 01/47883, WO 02/04425, WO 02/06246, WO 02/20497, WO 2005/016927 (in particular JTK003), WO 2004/041201, WO 2006/066079, WO 2006/066080, WO 2008/075103, WO 2009/010783 and WO 2009/010785; the content of each is incorporated herein by reference in its entirety.
  • additional non-nucleoside HCV NS5B polymerase inhibitors that are used in combination with the present HCV NS5B inhibitors are selected from the following compounds : 14-cyclohexyl-6- [2-(dimethylamino)ethyl] -7-oxo-5 , 6, 7, 8- tetrahydroindolo[2, l-a][2,5]benzodiazocine-l 1-carboxylic acid; 14-cyclohexyl-6-(2-morpholin- 4-ylethyl)-5,6,7,8-tetrahydroindolo[2, l-a][2,5]benzodiazocine-l 1-carboxylic acid; 14- cyclohexyl-6- [2-(dimethylamino)ethyl] -3 -methoxy-5 , 6, 7, 8-tetrahydroindolo [2, 1 -a]
  • the present HCV NS5B polymerase inhibitors are used in combination with non-nucleoside HCV NS5 A inhibitors and pharmaceutically acceptable salts thereof.
  • the HCV NS5B inhibitory activity of the present compounds may be tested using assays known in the art.
  • the HCV NS5B polymerase inhibitors described herein have activities in a genotype lb replicon assay as described in the Examples.
  • the assay is performed by incubating a replicon harboring cell-line in the presence of inhibitor for a set period of time and measuring the effect of the inhibitor on HCV replicon replication either directly by quantifying replicon RNA level, or indirectly by measuring enzymatic activity of a co-encoded reporter enzyme such as luciferase or ⁇ -lactamase.
  • the effective inhibitory concentration of the inhibitor (EC 50 or EC 90 ) is determined. See Jan M. Vrolijk et al., A replicons-based bioassay for the measurement of interferons in patients with chronic hepatitis C, 110 J. VlROLOGlCAL METHODS 201 (2003). Such assays may also be run in an automated format for high through-put screening. See Paul Zuck et al. , A cell-based ⁇ -lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication, 334 ANALYTICAL BIOCHEMISTRY 344 (2004). The present invention also includes processes for making Compounds of Formula (I).
  • the compounds of the present invention can be readily prepared according to the following reaction schemes and examples, or modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art, but are not mentioned in greater detail. Furthermore, other methods for preparing compounds of the invention will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. Unless otherwise indicated, all variables are as defined above. The following reaction schemes and examples serve only to illustrate the invention and its practice.
  • This scheme describes a method useful for making the compounds of formula M, which correspond to the Compounds of Formula (I) wherein BPin is pinacoldiborane; R 60 is para-F ; and R 10 , R 20 , R 30 , R 40 and R 50 are defined above for the Compounds of Formula (I).
  • a compound of formula A can be brominated, then esterified using TB ATB in MeOH to provide compounds of formula B.
  • the phenol group of B can then be protected as its TBS derivative to provide compounds of formula C, which can be acylated using 4- fluorobenzoyl chloride to provide compounds of formula D.
  • the phenol hydroxyl group of D can then be deproteced using TBAF, followed by an intramolecular acid-mediated cycliczation to provide compounds of formulas E and F sequentially.
  • a compound of formula F can subsequently be converted to a compound of formula G upon treatment with fuming HNO3.
  • Compounds of formula H can be obtained from compounds of formula G via reduction of the nitro group in G, and the resulting amino group in compouns of formula H can then be sulfonylated using a reagent of formula R 50 SO 2 Cl to provide sulfonamide compounds of formula I.
  • a compound of formula I can then be coupled with R 40 I in the presence of potassium carbonate to provide compounds of formula J, followed by base-catalyzed hydrolysis of the ester group in J to provide compounds of formula K.
  • the carboxylic acid group of K can then be condensed with an amine of formula R 30 H 2 in the presence of an amide-forming reagent, such as EDCI or HOBT, to provide compounds of formula L.
  • Transition-metal mediated coupling of the bromo moiety of L with a substituted phenyl boronic ester (alternatively boronic acid, alkyl tin, silicon, or other types of coupling partners may be used) finally provides the target compounds of formula M.
  • This scheme describes methods useful for making: (a) compounds of formula O, which correspond to the Compounds of Formula (I) wherein R 10 is benzthiazolyl; R 60 is para-F; and R 20 , R 30 , R 40 and R 50 are defined above for the Compounds of Formula (I), and (b) compounds of formula P, which correspond to the Compounds of Formula (I) wherein R 10 is benzimidazole or other bicyclic imidazole derivative; R is para-F; and R , R , R and R are defined above for the Compounds of Formula (I).
  • a compound of formula L can be coupled with a substituted or unsubstituted 3- formylphenylboronic acid using a transition metal catalyst, such as Pd(dppf)Cl 2 , to provide compounds of the formula N.
  • a transition metal catalyst such as Pd(dppf)Cl 2
  • Compounds of formula N are then cyclized with ortho amino thiophenols or ortho di-amino compounds to provide the target compounds of formulas O and P, respectively.
  • This scheme describes a method useful for making the compounds of formula T, which correspond to the Compounds of Formula (I) wherein Het is a heterocyclyl or heteroaryl group; R 60 is para-F; and R 20 , R 30 , R 40 and R 50 are defined above for the Compounds of Formula (I).
  • a compound of formula L can be coupled with a substituted or unsubstituted 3- nitrophenylboronic acid catalyzed by a transition metal, in this case Pd(dppf)Cl 2 , to provide the compounds of formula Q.
  • Compounds of formula Q can then be hydrogenated to provide the amino compounds of formula R, which are reacted with i-AmONO / I 2 , to provide the iodo compounds of formula S.
  • Transition metal mediated coupling of S with a heterocyclic boronic acid (alternatively boronic ester, alkyl tin, silicon, or other types of coupling partners may be used) provides the target compounds of formula T.
  • This scheme describes an alternate useful for making the compounds of formula T, which correspond to the Compounds of Formula (I) wherein Het is a heterocyclyl or heteroaryl group; R 60 is para-F; and R 20 , R 30 , R 40 and R 50 are defined above for the Compounds of Formula (I).
  • This scheme describes a method useful for making the the compounds of formula W, which correspond to the Compounds of Formula (I) wherein R 10 is indole or other bicyclic pyrrole derivative; R 60 is para-F; and R 20 , R 30 , R 40 and R 50 are defined above for the Compounds of Formula (I).
  • a transition metal-mediated coupling of a compound of a bromo compound of formula L with a heterocycle substituted phenyl boronic ester (alternatively boronic acid, alkyl tin, silicon, or other types of coupling partners may be used) provides the compounds of formula V.
  • the SEM protecting group of a compound of formula V can subsequently be deproteted using TBAF to provide the compounds of formula W.
  • This scheme describes an alternate method useful for making the compounds of formula T, which correspond to the Compounds of Formula (I) wherein Het is a heterocyclyl or heteroaryl group; R 60 is para-F; and R 20 , R 30 , R 40 and R 50 are defined above for the Compounds of Formula (I).
  • the ester group of a compound of formula I can be hydrolyzed using aqueous base to provide a compound of formula X.
  • the carboxylic acid moiety of X can then be condensed with an amine of formula R 30 H 2 using common amide forming reagents, such as EDCI and HOBT, to provide the compounds of formula Y.
  • the sulfonamide group of Y can then be coupled with a reagent of formula R 40 X in the presence of potassium carbonate or with a regent of formula R 40 OH in the presence of PPh 3 and DEAD to provide compounds of fomrula Z.
  • Transition metal mediated coupling of a compound of formula Z with a heterocycle-substituted phenyl boronic ester (alternatively boronic acid, alkyl tin, silicon, or other types of coupling partners may be used) provides the compounds of formula T.
  • This scheme describes yet another alternate method useful for making the compounds of formula T, which correspond to the Compounds of Formula (I) wherein Het is a heterocyclyl or heteroaryl group; R 60 is para-F; and R 20 , R 30 , R 40 and R 50 are defined above for the Compounds of Formula (I).
  • the amino group of a compound of formula I can be sulfonylated using a reagent of formula R 50 SO 2 Cl to provide the sulfonamide compounds of formula AA.
  • a compound of formula AA can then be coupled with a reactant of formula R 40 X in the presence of potassium carbonate to provide the compounds of formula AB.
  • the ester moiety of the compounds of formula AB can be readily hydrolyzed using aqueous base to provide the compounds of formula AC.
  • the carboxylic acid group of AC is then condensed with an amine of formula R 30 H 2 using common amide forming reagents, such as EDCI and HOBT, to provide the compounds of formula to AD.
  • Transition metal mediated coupling of a compound of formula AD with a heterocycle-substituted phenyl boronic ester (alternatively boronic acid, alkyl tin, silicon, or other types of coupling partners may be used) provides the compounds of formula T.
  • LiHMDS Lithium bis(trimethylsilyl) amide
  • Step 8 Synthesis of Methyl 5-bromo-2-(4-fluorophenyl)-6-(methylsulfonamido)-l-benzofuran- 3-carboxylate
  • Step 10 Synthesis of 5-bromo-2-(4-fluorophenyl)-6-(N-methylmethylsulfonamido)-l- benzofuran-3-carboxylic acid
  • methyl 5-bromo-2-(4-fluorophenyl)-6-(N- methylmethylsulfonamido)-l-benzofuran-3-carboxylate (20 g, 43.8 mmol) in dioxane / H 2 0 (1 / 1, 100 mL) was added LiOH-H 2 0 (18.39 g, 0.44 mol), and the mixture was heated to reflux for 3 hours, filtered and concentrated in vacuo.
  • Step 12 Synthesis of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(3- (oxazolo[ 4, 5-b ]pyridin-2-yl)phenyl)benzofuran-3-carboxamide (Compound 1)
  • Step 1 Synthesis of 5-(3-(6-aminobenzo[d]oxazol-2-yl)phenyl)-2-(4-fluorophenyl)-N-methyl-6- (N-methylmethylsulfonamido)benzofuran-3-carboxamide
  • Step 2 Synthesis of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(3-(6- (methylsulfonamido)benzo[d]oxazol-2-yl)phenyl)benzofuran-3-carboxamide (Compound 127)
  • Step 1 Synthesis of 2-(4-fluorophenyl)-5-(3-formylphenyl)-N-methyl-6-(N- methylmethylsulfonamido)benzofuran- -carboxamide l)
  • Step 2 Synthesis of 5-(3-(6-cyanobenzo[d]thiazol-2-yl)phenyl)-2-(4-fluorophenyl)-N-methyl-6- (N-methylmethylsulfonamido)benzofuran-3-carboxamide (Compound 134)
  • Step 1 Synthesis of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(3- nitrophenyl)benzofuran-3-carboxamide
  • Step 2 Synthesis of 5-(3-aminophenyl)-2-(4-fluorophenyl)-N-methyl-6-(N- methylmethylsulfonamido)benzofuran-3-carboxamide
  • Step 4 Synthesis of 5-(3-(benzo[b]thiophen-2-yl)phenyl)-2-(4-fluorophenyl)-N-methyl-6-(N- methylmethylsulfonamido)benzofuran-3-carboxamide (Compound 197)

Abstract

La présente invention concerne des composés de formule (I) qui sont utilisés en tant qu'inhibiteurs de polymérase du virus de l'hépatite C (VHC) NS5B, la synthèse de ces composés, et l'utilisation de ces composés pour inhiber l'activité polymérase VHC NS5B, pour traiter ou prévenir l'infection par le VHC et pour inhiber la réplication virale du VHC et/ou la production virale dans un système à base de cellules, Z, R30, R40, R50 et R60 des composés de formule (I) étant présentement définis comme indiqué dans la description.
PCT/CN2010/080332 2010-03-02 2010-12-27 Inhibiteurs de polymérase du virus de l'hépatite c ns5b WO2011106986A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PCT/CN2010/080332 WO2011106986A1 (fr) 2010-03-02 2010-12-27 Inhibiteurs de polymérase du virus de l'hépatite c ns5b
ARP110100621A AR080433A1 (es) 2010-03-02 2011-03-01 Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen.
TW100106743A TW201136919A (en) 2010-03-02 2011-03-01 Inhibitors of hepatitis C virus NS5B polymerase
CA2791426A CA2791426A1 (fr) 2010-03-02 2011-03-02 Inhibiteurs de polymerase du virus de l'hepatite c ns5b
EP11750145.2A EP2542545A4 (fr) 2010-03-02 2011-03-02 Inhibiteurs de polymérase du virus de l'hépatite c ns5b
PCT/CN2011/000332 WO2011106992A1 (fr) 2010-03-02 2011-03-02 Inhibiteurs de polymérase du virus de l'hépatite c ns5b
AU2011223394A AU2011223394A1 (en) 2010-03-02 2011-03-02 Inhibitors of hepatitis C virus NS5B polymerase
US13/582,240 US20120328569A1 (en) 2010-03-02 2011-03-02 Inhibitors of hepatitis c virus ns5b polymerase
JP2012555284A JP2013521237A (ja) 2010-03-02 2011-03-02 Ｃ型肝炎ウィルスｎｓ５ｂポリメラーゼの阻害薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2010/070831 WO2011106929A1 (fr) 2010-03-02 2010-03-02 Inhibiteurs de polymérase du virus de l'hépatite c ns5b
CNPCT/CN2010/070831 2010-03-02
PCT/CN2010/080332 WO2011106986A1 (fr) 2010-03-02 2010-12-27 Inhibiteurs de polymérase du virus de l'hépatite c ns5b

Publications (1)

Publication Number Publication Date
WO2011106986A1 true WO2011106986A1 (fr) 2011-09-09

Family

ID=52460414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2010/080332 WO2011106986A1 (fr) 2010-03-02 2010-12-27 Inhibiteurs de polymérase du virus de l'hépatite c ns5b

Country Status (1)

Country Link
WO (1) WO2011106986A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103224479A (zh) * 2013-04-26 2013-07-31 温州大学 一种2-芳基苯并呋喃类化合物的合成方法
US8614207B2 (en) 2010-10-26 2013-12-24 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis C virus
US8927593B2 (en) 2011-08-19 2015-01-06 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis C virus infections
WO2015179392A1 (fr) * 2014-05-21 2015-11-26 Bristol-Myers Squibb Company Composés 2-(aryl- ou hétéroaryl-)phényl(aza)benzofurane pour le traitement de l'hépatite c
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1731993A (zh) * 2002-11-01 2006-02-08 维洛药品公司 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1731993A (zh) * 2002-11-01 2006-02-08 维洛药品公司 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8614207B2 (en) 2010-10-26 2013-12-24 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis C virus
US9085587B2 (en) 2010-10-26 2015-07-21 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis C virus
US9309260B2 (en) 2010-10-26 2016-04-12 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis C virus
US8927593B2 (en) 2011-08-19 2015-01-06 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis C virus infections
US9682999B2 (en) 2011-08-19 2017-06-20 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis C virus infections
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN103224479A (zh) * 2013-04-26 2013-07-31 温州大学 一种2-芳基苯并呋喃类化合物的合成方法
CN103224479B (zh) * 2013-04-26 2014-10-15 温州大学 一种2-芳基苯并呋喃类化合物的合成方法
WO2015179392A1 (fr) * 2014-05-21 2015-11-26 Bristol-Myers Squibb Company Composés 2-(aryl- ou hétéroaryl-)phényl(aza)benzofurane pour le traitement de l'hépatite c

Similar Documents

Publication Publication Date Title
WO2011106992A1 (fr) Inhibiteurs de polymérase du virus de l'hépatite c ns5b
TWI494309B (zh) Ｃ型肝炎病毒（ｈｃｖ）nｓ５ａ抑制劑
CN102427729B (zh) 丙型肝炎病毒复制的抑制剂
JP5735482B2 (ja) 縮合環のｃ型肝炎阻害剤
TWI480278B (zh) Ｃ型肝炎病毒（ｈｃｖ）ｎｓ５ａ之抑制劑
JP5685191B2 (ja) Ｃ型肝炎の治療のための化合物
WO2011106929A1 (fr) Inhibiteurs de polymérase du virus de l'hépatite c ns5b
WO2012067664A1 (fr) Composés
ES2611731T3 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de la hepatitis C
MX2011002471A (es) Compuestos para el tratamiento de la hepatitis c.
EP2953456A1 (fr) Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
TW201138786A (en) Therapeutic compounds
WO2011106986A1 (fr) Inhibiteurs de polymérase du virus de l'hépatite c ns5b
EP2953462B1 (fr) Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
EP3013834A1 (fr) Composés benzofuranes substitués et leurs méthodes d'utilisation pour le traitement de maladies virales
WO2014209726A1 (fr) Composés benzofuranes substitués et leurs méthodes d'utilisation pour le traitement de maladies virales
JP2018509401A (ja) Ｃ型肝炎の治療のための新規化合物
JP2013540134A (ja) ウイルスポリメラーゼ阻害剤
EP2953461B1 (fr) Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10846904

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10846904

Country of ref document: EP

Kind code of ref document: A1